|
|
Article: Drug raises BMD in ADT recipients: in a study of PCa patients, denosumab also decreased the risk of new vertebral fractures.
- Article from:
- Renal & Urology News
- Article date:
- October 1, 2009
CopyrightCOPYRIGHT 2009 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DENOSUMAB MAY increase bone mineral density (BMD) and reduce the incidence of new vertebral fractures in men receiving androgendeprivation therapy (ADT) for nonmetastatic prostate cancer (PCa), a study shows.
The drug is a fully human monoclonal antibody that binds specifically to the receptor activator of a key mediator of osteoclast formation, function, and survival.
In a double-blind study of 1,468 patients (mean age 75 years) receiving ADT for nonmetastatic PCa, Matthew R. Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center in Boston, randomly assigned 734 subjects to receive denosumab at a dose of 60 mg subcutaneously every six ...